ReCode in the News
Press Releases
Menlo Park, Calif. – March 25, 2025 – ReCode Therapeutics, a clinical-stage genetic medicines company using
ReCode Therapeutics Announces Additional Funding from the Cystic Fibrosis Foundation to Accelerate Development of Novel Gene Correction Therapeutics to Treat Cystic Fibrosis
ReCode, Cystic Fibrosis Foundation Advance CF Gene Therapies
ReCode Announces Two Key Additions to Scientific Advisory Board
ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave
ReCode Therapeutics Presents Preclinical Data from its Cystic Fibrosis Program at the 2024 North American Cystic Fibrosis Conference (NACFC) in Boston
ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave
Media Contacts
The Grace Communication Group
Tara Cooper
[email protected]
[email protected]
Investor Contact
Stern IR
AnneMarie Fields
[email protected]
[email protected]
Media Library
Download assets including ReCode’s logo, high-resolution headshots, and fact sheets.
Presentations
Nebulized LNP-formulated DNAI1 mRNA Therapy to Restore Mucociliary Clearance for the Treatment of Primary Ciliary Dyskinesia
2023 Cilia, Mucus and Mucociliary Interactions GRC
Aerosolized lipid nanoparticle/mRNA therapy to treat patients with Cystic Fibrosis
2023 Cilia, Mucus and Mucociliary Interactions GRC
Rescue of Ciliary Function in Primary Ciliary Dyskinesia using Nebulized LNP-formulated DNAI1 mRNA
5th European Cilia Conference
Publications & Abstracts
Featured News
Unshackling genetic medicines by enabling delivery beyond the liver
Nature Biopharma Dealmakers
Media Contacts
ReCode Therapeutics
Erica Jefferson
[email protected]
The Grace Group
Tara Cooper
[email protected]
[email protected]
Investor Contact
Stern IR
AnneMarie Fields
[email protected]
[email protected]
Media Library
Download assets including ReCode’s logo, high-resolution headshots, and fact sheets.